Walleye Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Walleye Capital’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,333	Closed	-$2.43M	–	4992
2026 Q1	$2.06M	Buy	+10,333	New	+$2.04M	0.01%	1439
2025 Q1	–	Sell	-209	Closed	-$22.4K	–	4718
2024 Q4	$22.4K	Sell	209 -546	-72%	-$61.7K	﹤0.01%	4488
2024 Q3	$75.6K	Buy	+755	New	+$76K	﹤0.01%	4512
2023 Q4	–	Sell	-2,469	Closed	-$146K	–	5253
2023 Q3	$148K	Buy	+2,469	New	+$163K	﹤0.01%	3742
2023 Q2	–	Sell	-10,078	Closed	-$741K	–	4623
2023 Q1	$741K	Sell	10,078 -1,339	-12%	-$95.2K	0.01%	1371
2022 Q4	$763K	Buy	11,417 +5,540	+94%	+$360K	0.01%	1166
2022 Q3	$316K	Sell	5,877 -1,835	-24%	-$108K	0.01%	1804
2022 Q2	$429K	Buy	+7,712	New	+$438K	0.01%	1125

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's LGND Position: Q2 2026 in Review

Walleye Capital sold out of Ligand Pharmaceuticals (LGND) in Q2 2026, closing a stake of 10,333 shares — an estimated $2.43M sold.

Walleye Capital first reported a position in LGND in Q2 2022 and held it in 8 quarters. The position peaked at $2.06M in Q1 2026. 414 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Walleye Capital reported no remaining Ligand Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Walleye Capital sold 10,333 Ligand Pharmaceuticals shares in Q2 2026, an estimated $2.43M.
Walleye Capital first reported a position in Ligand Pharmaceuticals in Q2 2022 and held it in 8 quarters.
Walleye Capital's Ligand Pharmaceuticals position peaked at $2.06M in Q1 2026.
414 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.